(Total Views: 996)
Posted On: 07/12/2020 4:39:07 PM
Post# of 148936
Hi guys I have more material information
CoolBeans membership is mostly FMG's trying to prepare for the entry medical exams into the US, Not sure how many practicing and more importantly prescribing physicians watch, but it is a start...
I just had lunch with my best friend an ID boarded with a particular interest in AIDS.
Summary: current treatment protocols bring viral load to zero using PCR assays. The challenge is compliance, they are only Qd oral dosing. Although there numerous prophylactic drugs in the pipeline they may not gain popularity with prescribers for the above reasons. There is also another HIV entry blocker available and in phase 4 trials. Which would be in direct competition with leronilmab.
He is a huge supporter of leronilmab, and a stock holder. Here in Michigan he reported a large spike in the COVID unit he runs we all know about Florida which is reaching ICU capacity. Redemsivir is a pain to prescribe, due to restrictions, and FDA paperwork, it is not approved.
The recent published study from Henry Ford Health system (in my backyard also seems promising) using plaqenil for treatment and prophylaxis, he is using it. My old hospital is using Narcan and Ketamine with early positive results, and you know Dr. Been is a fan of the anti lice drug.
Now the great news :
His mentor at UAB, Dr. Sarr the world renown expert in HIV and the author of one of the most comprehensive books on the disease will be contacted by my friend this week. He is also sending letters/editorial comments to the blue and red journal the bibles of ID.
We are are embarking on a search on the NCIB data base of all publications where leronilmad is mentioned and cross reference with the citation index to try to calculate clinician interest. He is also willing to consider joining the speaker bureau when appropriate.
CoolBeans membership is mostly FMG's trying to prepare for the entry medical exams into the US, Not sure how many practicing and more importantly prescribing physicians watch, but it is a start...
I just had lunch with my best friend an ID boarded with a particular interest in AIDS.
Summary: current treatment protocols bring viral load to zero using PCR assays. The challenge is compliance, they are only Qd oral dosing. Although there numerous prophylactic drugs in the pipeline they may not gain popularity with prescribers for the above reasons. There is also another HIV entry blocker available and in phase 4 trials. Which would be in direct competition with leronilmab.
He is a huge supporter of leronilmab, and a stock holder. Here in Michigan he reported a large spike in the COVID unit he runs we all know about Florida which is reaching ICU capacity. Redemsivir is a pain to prescribe, due to restrictions, and FDA paperwork, it is not approved.
The recent published study from Henry Ford Health system (in my backyard also seems promising) using plaqenil for treatment and prophylaxis, he is using it. My old hospital is using Narcan and Ketamine with early positive results, and you know Dr. Been is a fan of the anti lice drug.
Now the great news :
His mentor at UAB, Dr. Sarr the world renown expert in HIV and the author of one of the most comprehensive books on the disease will be contacted by my friend this week. He is also sending letters/editorial comments to the blue and red journal the bibles of ID.
We are are embarking on a search on the NCIB data base of all publications where leronilmad is mentioned and cross reference with the citation index to try to calculate clinician interest. He is also willing to consider joining the speaker bureau when appropriate.
(17)
(0)Scroll down for more posts ▼
